Works matching DE "IPRAGLIFLOZIN"

Results: 70
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)

    Published in:
    Diabetes, Obesity & Metabolism, 2019, v. 21, n. 8, p. 1990, doi. 10.1111/dom.13750
    By:
    • Koshizaka, Masaya;
    • Ishikawa, Ko;
    • Ishibashi, Ryoichi;
    • Maezawa, Yoshiro;
    • Sakamoto, Kenichi;
    • Uchida, Daigaku;
    • Nakamura, Susumu;
    • Yamaga, Masaya;
    • Yokoh, Hidetaka;
    • Kobayashi, Akina;
    • Onishi, Shunichiro;
    • Kobayashi, Kazuki;
    • Ogino, Jun;
    • Hashimoto, Naotake;
    • Tokuyama, Hirotake;
    • Shimada, Fumio;
    • Ohara, Emi;
    • Ishikawa, Takahiro;
    • Shoji, Mayumi;
    • Ide, Shintaro
    Publication type:
    Article
    12
    13

    Comparative study of the effects of ipragliflozin and sitagliptin on multiple metabolic variables in Japanese patients with type 2 diabetes: A multicentre, randomized, prospective, open‐label, active‐controlled study.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 11, p. 2675, doi. 10.1111/dom.13421
    By:
    • Tsurutani, Yuya;
    • Nakai, Kazuki;
    • Inoue, Kosuke;
    • Azuma, Kosuke;
    • Mukai, Sei;
    • Maruyama, Seitaro;
    • Iizuka, Takashi;
    • Matsuzawa, Yoko;
    • Saito, Jun;
    • Omura, Masao;
    • Nishikawa, Tetsuo
    Publication type:
    Article
    14

    Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial.

    Published in:
    Diabetes, Obesity & Metabolism, 2018, v. 20, n. 10, p. 2408, doi. 10.1111/dom.13394
    By:
    • Han, Kyung‐ah;
    • Chon, Suk;
    • Chung, Choon Hee;
    • Lim, Soo;
    • Lee, Kwan‐woo;
    • Baik, Seihyun;
    • Jung, Chang Hee;
    • Kim, Dong‐sun;
    • Park, Kyong Soo;
    • Yoon, Kun‐ho;
    • Lee, In‐kyu;
    • Cha, Bong‐soo;
    • Sakatani, Taishi;
    • Park, Sumi;
    • Lee, Moon‐kyu
    Publication type:
    Article
    15
    16
    17

    A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the Long-Term ASP1941 Safety Evaluation in Patients with Type 2 Diabetes with Renal Impairment (LANTERN) study

    Published in:
    Diabetes, Obesity & Metabolism, 2015, v. 17, n. 2, p. 152, doi. 10.1111/dom.12403
    By:
    • Kashiwagi, A.;
    • Takahashi, H.;
    • Ishikawa, H.;
    • Yoshida, S.;
    • Kazuta, K.;
    • Utsuno, A.;
    • Ueyama, E.
    Publication type:
    Article
    18

    Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model.

    Published in:
    PLoS ONE, 2022, v. 17, n. 2, p. 1, doi. 10.1371/journal.pone.0261310
    By:
    • Morishita, Asahiro;
    • Tadokoro, Tomoko;
    • Fujihara, Shintaro;
    • Iwama, Hisakazu;
    • Oura, Kyoko;
    • Fujita, Koji;
    • Tani, Joji;
    • Takuma, Kei;
    • Nakahara, Mai;
    • Shi, Tingting;
    • Haba, Reiji;
    • Okano, Keiichi;
    • Nishiyama, Akira;
    • Ono, Masafumi;
    • Himoto, Takashi;
    • Masaki, Tsutomu
    Publication type:
    Article
    19

    Metabolomic analysis of serum samples from a clinical study on ipragliflozin and metformin treatment in Japanese patients with type 2 diabetes: Exploring human metabolites associated with visceral fat reduction.

    Published in:
    Pharmacotherapy, 2023, v. 43, n. 12, p. 1317, doi. 10.1002/phar.2884
    By:
    • Tsukagoshi‐Yamaguchi, Ayano;
    • Koshizaka, Masaya;
    • Ishibashi, Ryoichi;
    • Ishikawa, Ko;
    • Ishikawa, Takahiro;
    • Shoji, Mayumi;
    • Ide, Shintaro;
    • Ide, Kana;
    • Baba, Yusuke;
    • Terayama, Ryo;
    • Hattori, Akiko;
    • Takemoto, Minoru;
    • Ouchi, Yasuo;
    • Maezawa, Yoshiro;
    • Yokote, Koutaro
    Publication type:
    Article
    20
    21
    22
    23

    Long‐term effects of ipragliflozin and pioglitazone on metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes: 5 year observational follow‐up of a randomized, 24 week, active‐controlled trial: Effect of ipragliflozin in MASLD

    Published in:
    Journal of Diabetes Investigation, 2024, v. 15, n. 9, p. 1220, doi. 10.1111/jdi.14246
    By:
    • Ito, Daisuke;
    • Shimizu, Satoshi;
    • Haisa, Akifumi;
    • Yanagisawa, Shinnosuke;
    • Inoue, Kazuyuki;
    • Saito, Daigo;
    • Sumita, Takashi;
    • Yanagisawa, Morifumi;
    • Uchida, Yoshihito;
    • Inukai, Kouichi;
    • Shimada, Akira
    Publication type:
    Article
    24

    Effects of ipragliflozin versus metformin in combination with sitagliptin on bone and muscle in Japanese patients with type 2 diabetes mellitus: Subanalysis of a prospective, randomized, controlled study (PRIME‐V study).

    Published in:
    Journal of Diabetes Investigation, 2021, v. 12, n. 2, p. 200, doi. 10.1111/jdi.13340
    By:
    • Koshizaka, Masaya;
    • Ishikawa, Ko;
    • Ishibashi, Ryoichi;
    • Maezawa, Yoshiro;
    • Sakamoto, Kenichi;
    • Uchida, Daigaku;
    • Nakamura, Susumu;
    • Yamaga, Masaya;
    • Yokoh, Hidetaka;
    • Kobayashi, Akina;
    • Onishi, Shunichiro;
    • Kobayashi, Kazuki;
    • Ogino, Jun;
    • Hashimoto, Naotake;
    • Tokuyama, Hirotake;
    • Shimada, Fumio;
    • Ohara, Emi;
    • Ishikawa, Takahiro;
    • Shoji, Mayumi;
    • Ide, Shintaro
    Publication type:
    Article
    25
    26
    27

    Effects of ipragliflozin on glycemic control, appetite and its related hormones: A prospective, multicenter, open‐label study (SOAR‐KOBE Study).

    Published in:
    Journal of Diabetes Investigation, 2019, v. 10, n. 5, p. 1254, doi. 10.1111/jdi.13015
    By:
    • Miura, Hiroshi;
    • Sakaguchi, Kazuhiko;
    • Okada, Yuko;
    • Yamada, Tomoko;
    • Otowa‐Suematsu, Natsu;
    • So, Anna;
    • Komada, Hisako;
    • Hirota, Yushi;
    • Ohara, Takeshi;
    • Kuroki, Yasuo;
    • Hara, Kenta;
    • Matsuda, Tomokazu;
    • Kishi, Minoru;
    • Takeda, Akihiko;
    • Yokota, Kazuki;
    • Tamori, Yoshikazu;
    • Ogawa, Wataru
    Publication type:
    Article
    28

    Ipragliflozin, a sodium–glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.

    Published in:
    Journal of Diabetes Investigation, 2019, v. 10, n. 4, p. 1012, doi. 10.1111/jdi.12985
    By:
    • Inoue, Hideka;
    • Morino, Katsutaro;
    • Ugi, Satoshi;
    • Tanaka‐Mizuno, Sachiko;
    • Fuse, Keiko;
    • Miyazawa, Itsuko;
    • Kondo, Keiko;
    • Sato, Daisuke;
    • Ohashi, Natsuko;
    • Ida, Shogo;
    • Sekine, Osamu;
    • Yoshimura, Masahiro;
    • Murata, Kiyoshi;
    • Miura, Katsuyuki;
    • Arima, Hisatomi;
    • Maegawa, Hiroshi
    Publication type:
    Article
    29

    Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.

    Published in:
    Journal of Diabetes Investigation, 2019, v. 10, n. 2, p. 429, doi. 10.1111/jdi.12913
    By:
    • Takahashi, Kiyohiko;
    • Cho, Kyu Yong;
    • Nakamura, Akinobu;
    • Miya, Aika;
    • Miyoshi, Arina;
    • Yamamoto, Chiho;
    • Nomoto, Hiroshi;
    • Niwa, Hirokatsu;
    • Takahashi, Kiyohito;
    • Manda, Naoki;
    • Kurihara, Yoshio;
    • Aoki, Shin;
    • Ito, Yoichi M;
    • Atsumi, Tatsuya;
    • Miyoshi, Hideaki
    Publication type:
    Article
    30
    31
    32
    33
    34
    35

    Effects of a sodium glucose co-transporter 2 selective inhibitor, ipragliflozin, on the diurnal profile of plasma glucose in patients with type 2 diabetes: A study using continuous glucose monitoring.

    Published in:
    Journal of Diabetes Investigation, 2015, v. 6, n. 6, p. 699, doi. 10.1111/jdi.12370
    By:
    • Yamada, Kentaro;
    • Nakayama, Hitomi;
    • Yoshinobu, Satoko;
    • Kawano, Seiko;
    • Tsuruta, Munehisa;
    • Nohara, Masayuki;
    • Hasuo, Rika;
    • Akasu, Shoko;
    • Tokubuchi, Ichiro;
    • Wada, Nobuhiko;
    • Hirao, Saori;
    • Iwata, Shinpei;
    • Kaku, Hiroo;
    • Tajiri, Yuji
    Publication type:
    Article
    36
    37
    38

    Comparison of Ipragliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes: A Randomized, 24-Week, Open-Label, Active-Controlled Trial.

    Published in:
    2017
    By:
    • Daisuke Ito;
    • Satoshi Shimizu;
    • Kazuyuki Inoue;
    • Daigo Saito;
    • Morifumi Yanagisawa;
    • Kouichi Inukai;
    • Yuji Akiyama;
    • Yoshihiro Morimoto;
    • Mitsuhiko Noda;
    • Akira Shimada;
    • Ito, Daisuke;
    • Shimizu, Satoshi;
    • Inoue, Kazuyuki;
    • Saito, Daigo;
    • Yanagisawa, Morifumi;
    • Inukai, Kouichi;
    • Akiyama, Yuji;
    • Morimoto, Yoshihiro;
    • Noda, Mitsuhiko;
    • Shimada, Akira
    Publication type:
    journal article
    39
    40
    41
    42
    43
    44

    Impact of baseline left ventricular ejection fraction and body mass index on the effect of 24-week Ipragliflozin treatment on left ventricular diastolic function in patients with type 2 diabetes and chronic kidney disease: insights from the PROCEED trial.

    Published in:
    Cardiovascular Diabetology, 2025, v. 24, n. 1, p. 1, doi. 10.1186/s12933-025-02745-1
    By:
    • Teragawa, Hiroki;
    • Tanaka, Atsushi;
    • Takahashi, Kanae;
    • Oshita, Chikage;
    • Uchimura, Yuko;
    • Kamei, Nozomu;
    • Hirai, Hiroyuki;
    • Shimabukuro, Michio;
    • Taguchi, Isao;
    • Okada, Yosuke;
    • Node, Koichi
    Publication type:
    Article
    45
    46
    47
    48
    49
    50